Following the announcement of significant business expansion, shares of OneMedNet Corporation (NASDAQ: ONMD) have experienced a substantial increase, rising by 56.46% to $2.25 during last Friday session. This growth on the US stock charts reflects the market’s positive response to the company’s recent strategic developments.
Expansion Of iRWD Network
OneMedNet (ONMD) has disclosed a remarkable expansion of its proprietary iRWD network and platform, growing more than fivefold. This expansion is facilitated through several new network partnership agreements, including a notable agreement with a prominent nationwide medical records custodian.
As a result, OneMedNet now offers its expanding customer base enhanced access to a broader array of Real World Data (RWD) across its extensive network. This network now encompasses 1,402 healthcare system and provider partner sites, serves 31.0 million patients, and includes data from 121.4 million clinical exams.
The year-to-date increases in partner sites, patients, and clinical exams represent growth rates of 472%, 170%, and 122%, respectively, since the end of 2023. This substantial network expansion demonstrates OneMedNet’s effective execution of its growth strategy. The company is committed to leveraging the full potential of RWD to drive healthcare innovation.
By providing customers with comprehensive access to valuable, regulatory-grade clinical data, OneMedNet is not merely increasing data quantity but is also delivering the critical, de-identified information necessary to usher in a new era of medical excellence.
Partnership With ClinEco
Recently, OneMedNet has been invited to join ClinEco Inc., a connectivity platform and community that enhances access, expands distribution, and promotes efficient partner interactions and accelerated clinical innovation. This invitation underscores the credibility of OneMedNet’s RWD platform as a trusted source of precision, regulatory-grade clinical data. The effective utilization of RWD in clinical research is rapidly expanding, necessitating collaboration among all participants to achieve growth.
ClinEco, as the world’s first B2B market network for clinical trials, brings together sponsors, CROs, service providers, and sites, enabling members to explore, engage, and exchange capabilities within their ecosystem of partners. For OneMedNet, ClinEco will be an invaluable platform for educating and efficiently providing precise, high-quality RWD to drive insights for life science members.
